Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPT1G Phase 1 First-in-Human Study in Healthy Adults
NCT06667765Phase 1Completed
- Sponsor
- Remedy Plan Therapeutics
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RPT1G in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Remedy Plan Therapeutics. Primary endpoint: Safety of RPT1G by number of adverse events. Started Nov 2024; status: completed.
02
Drugs
RPT1G
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06667765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667765.